{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:17:50Z","timestamp":1781014670660,"version":"3.54.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,12]]},"DOI":"10.1093\/infdis\/jix482","type":"journal-article","created":{"date-parts":[[2017,9,13]],"date-time":"2017-09-13T11:08:56Z","timestamp":1505300936000},"page":"1343-1351","source":"Crossref","is-referenced-by-count":50,"title":["Immunogenicity and Safety of the HZ\/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine"],"prefix":"10.1093","volume":"216","author":[{"given":"Katrijn","family":"Grupping","sequence":"first","affiliation":[{"name":"GSK Vaccine, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Campora","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Douha","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C","family":"Heineman","sequence":"additional","affiliation":[{"name":"Genocea Biosciences, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola P","family":"Klein","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Vaccine Study Center, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Lal","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peterson","sequence":"additional","affiliation":[{"name":"Foothill Family Clinic, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Vastiau","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Oostvogels","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"key":"key\n\t\t\t\t20180306120546_CIT0001","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJMcp1302674","article-title":"Clinical practice: herpes zoster","volume":"369","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306120546_CIT0002","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/bmj.321.7264.778","article-title":"The management of post-herpetic neuralgia","volume":"321","author":"Cunningham","year":"2000","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180306120546_CIT0003","first-page":"S13","article-title":"Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence","volume":"109","author":"Oxman","year":"2009","journal-title":"J Am Osteopath Assoc"},{"key":"key\n\t\t\t\t20180306120546_CIT0004","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0005","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J Clin Virol"},{"key":"key\n\t\t\t\t20180306120546_CIT0006","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1286-4579(01)01443-5","article-title":"Immunosenescence and infectious diseases","volume":"3","author":"Ginaldi","year":"2001","journal-title":"Microbes Infect"},{"key":"key\n\t\t\t\t20180306120546_CIT0007","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180306120546_CIT0008","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-015-1262-8","article-title":"Annual incidence rates of herpes zoster among an immunocompetent population in the United States","volume":"15","author":"Johnson","year":"2015","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0009","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180306120546_CIT0010","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijid.2015.03.022","article-title":"Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia","volume":"34","author":"Kawai","year":"2015","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0011","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"key\n\t\t\t\t20180306120546_CIT0012","first-page":"CD006866","article-title":"Antiviral treatment for preventing postherpetic neuralgia","author":"Li","year":"2009:","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20180306120546_CIT0013","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1186\/s12889-015-1861-8","article-title":"Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries","volume":"15","author":"Damm","year":"2015","journal-title":"BMC Public Health"},{"key":"key\n\t\t\t\t20180306120546_CIT0014","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306120546_CIT0016","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the short-term persistence substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0017","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0018","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1365-2249.2008.03633.x","article-title":"Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors","volume":"152","author":"Malavige","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t20180306120546_CIT0019","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/0264-410X(94)00073-V","article-title":"Boosting immune response with a candidate varicella-zoster virus glycoprotein subunit vaccine","volume":"13","author":"Vafai","year":"1995","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180306120546_CIT0020","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","article-title":"Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells","volume":"193","author":"Didierlaurent","year":"2014","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20180306120546_CIT0021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20180306120546_CIT0022","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","article-title":"Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study","volume":"32","author":"Chlibek","year":"2014","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180306120546_CIT0023","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0024","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jis497","article-title":"A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults","volume":"206","author":"Leroux-Roels","year":"2012","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","volume":"34","author":"Chlibek","year":"2016","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20180306120546_CIT0026","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306120546_CIT0027","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306120546_CIT0028","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/infdis\/jiv480","article-title":"Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults","volume":"213","author":"Levin","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306120546_CIT0031","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4161\/hv.24269","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ\/su): a phase-I, open-label study in Japanese adults","volume":"9","author":"Lal","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"key\n\t\t\t\t20180306120546_CIT0032","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/11\/1343\/24263706\/jix482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T12:06:07Z","timestamp":1570104367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/11\/1343\/4209275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,9,20]]},"published-print":{"date-parts":[[2017,12,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix482","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,1]]},"published":{"date-parts":[[2017,9,20]]}}}